
The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …

Pfizer has said its sickle cell drug rivipansel failed to meet its primary endpoint or key secondary endpoints in a …

The NHS Commissioning Board has launched a consultation into how the NHS provides specialised services, including treatments for conditions such …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

